Estadístiques de An open-label, multicenter, randomized, phase II study of Cisplatin and Pemetrexed with or without Cixutumumab (IMC-A12) as a first-line therapy in patients with advanced nonsquamous non-small cell lung cancer.
Visites totals
| views | |
|---|---|
| An open-label, multicenter, randomized, phase II study of Cisplatin and Pemetrexed with or without Cixutumumab (IMC-A12) as a first-line therapy in patients with advanced nonsquamous non-small cell lung cancer. | 308 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| novello-jto-anop.pdf(legacy) | 268 |
| novello-jto-anop.pdf | 31 |
Vistes principals per país
| views | |
|---|---|
| United States | 177 |
| Germany | 71 |
| France | 20 |
| Ireland | 10 |
| Spain | 5 |
| India | 4 |
| Poland | 4 |
| Belgium | 3 |
| Sweden | 3 |
| United Kingdom | 2 |
| Italy | 2 |
| Ukraine | 2 |
| Canada | 1 |
| Czechia | 1 |
| Malaysia | 1 |
| Venezuela | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ashburn | 46 |
| Fairfield | 25 |
| San Ramon | 18 |
| Dublin | 10 |
| Leawood | 9 |
| Mountain View | 8 |
| Ann Arbor | 7 |
| Nürnberg | 7 |
| Cambridge | 6 |
| San Diego | 6 |
| Boardman | 5 |
| Seattle | 5 |
| Barcelona | 4 |
| Dearborn | 3 |
| Portland | 2 |
| Rezé | 2 |
| Andover | 1 |
| Caracas | 1 |
| Des Moines | 1 |
| Hyderabad | 1 |
| Jacksonville | 1 |
| Magdeburg | 1 |
| Menlo Park | 1 |
| Montréal | 1 |
| Mumbai | 1 |
| Petaling Jaya | 1 |
| Phoenix | 1 |
| Premiá De Mar | 1 |
| Pune | 1 |
| Redwood City | 1 |
| Sacramento | 1 |
| Tustin | 1 |